Alignment Healthcare CEO sells 180,000 shares

Alignment Healthcare, Inc. director and CEO John E. Kao reported an open-market sale of 180,000 shares of common stock at a weighted-average price of $18.1864 per share on March 10, 2026.

Rhea-AI Filing Summary

Alignment Healthcare, Inc. director and CEO John E. Kao reported an open-market sale of 180,000 shares of common stock at a weighted-average price of $18.1864 per share on March 10, 2026. The shares were held indirectly through the JEK Trust, where he serves as trustee. Following the sale, indirect holdings reported for the trust were 2,472,641 shares, and his direct holdings were 1,568,379 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 12, 2025.

Insider Trade Summary 10b5-1

Net Seller: 180,000 shares

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 180,000 shs ($3.27M)

Type	Security	Shares	Price	Value
Sale	Common Stock	180,000	$18.1864	$3.27M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,472,641 shares (Indirect, See Footnote); Common Stock — 1,568,379 shares (Direct)

Footnotes (3)

1. F1. Date of Rule 10b5-1 plan adoption: 03/12/2025
2. F2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $17.86 to $18.57. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
3. F3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alignment Healthcare (ALHC) report for John E. Kao?

Alignment Healthcare CEO John E. Kao reported selling 180,000 shares of common stock. The sale occurred on March 10, 2026, at a weighted-average price of $18.1864 per share through an open-market transaction reported on Form 4.

At what prices were John E. Kao’s Alignment Healthcare (ALHC) shares sold?

The reported sale used a weighted-average price of $18.1864 per share. According to the disclosure, individual trades occurred between $17.86 and $18.57 per share, with detailed trade breakdowns available upon request from the company or regulators.

How many Alignment Healthcare (ALHC) shares does John E. Kao hold after this sale?

After the reported sale, John E. Kao’s indirect holdings through the JEK Trust were 2,472,641 shares, and his direct holdings were 1,568,379 shares. These totals reflect the positions reported immediately following the March 10, 2026 transaction.

Were John E. Kao’s Alignment Healthcare (ALHC) share sales pre-planned?

Yes. The filing states the transactions were under a Rule 10b5-1 trading plan adopted on March 12, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing for interpreting insider activity.

How are the sold Alignment Healthcare (ALHC) shares held for John E. Kao?

The 180,000 sold shares were held indirectly through the JEK Trust dated February 8, 2021. John E. Kao serves as trustee of this trust, and the filing attributes the reported indirect ownership to that structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 07:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		S(1)		180,000	D	$18.1864(2)	2,472,641	I	See Footnote(3)
Common Stock								1,568,379	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/12/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $17.86 to $18.57. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.